Drug distributor Cardinal Health warned on Tuesday that its business might be hurt because it defends itself against a number of opioid-related suits.
A number of pharmaceutical wholesale distributors, including Cardinal, have been named as defendants in about 2,500 suits for the distribution of prescription opioid ache drugs. These suits have been filed in various federal, state, and different courts by a variety of plaintiffs.
Cardinal mentioned in a filing it expects to be named as a defendant in further lawsuits.
Drug manufacturers and distributors have been partly blamed for the U.S. opioid crisis, accused of deceptively advertising opioids in ways that downplayed their risks.
AmerisourceBergen Corp and McKesson Corp are additionally dealing with similar lawsuits.
Cardinal stated it was actively defending itself in all opioid-linked issues; however, is unable to predict their result or estimate a range of possible losses.
Cardinal said that ongoing destructive publicity might hurt its reputation or outcomes of operations.
Opioids were involved in 400,000 overdose deaths from 1999 to 2017, in response to the U.S. Centers for Disease Control and Prevention.
On Tuesday, drug manufacturers Endo Worldwide and Allergan agreed to pay $15 million to avoid going to trial in October in a landmark opioid-linked case by two Ohio divisions.
Earlier this month, a report notes that McKesson, Cardinal Health and AmerisourceBergen had suggested paying a $10 billion settlement for claims that they played a part in the U.S. opioid crisis.